← feed

Is NCT05341102 results overdue?

Yes — results are overdue. Primary completion was 2017-06-02; the FDAAA-801 reporting deadline (2018-06-02) passed 2941 days ago and no results are posted on ClinicalTrials.gov.

A Study of Single and Repeated Doses of LY3556050 in Healthy Participants

NCT IDNCT05341102 ↗
SponsorEli Lilly and Company (INDUSTRY)
Public issuerELI LILLY & Co — LLY (CIK 0000059478) best-effort name match, 82% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2017-06-02 (ACTUAL)
Reporting deadline2018-06-02 (completion + 365d)
Days overdue2941
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 354a414948c55db4… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT05341102. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →